New enzyme treatment may shorten hospital stays for bone cancer patients
NCT ID NCT03960177
First seen Jan 11, 2026 · Last updated May 09, 2026 · Updated 25 times
Summary
This early-phase trial tests whether the drug glucarpidase can safely lower the toxic side effects of high-dose methotrexate in adults with osteosarcoma (a type of bone cancer). The study involves 12 participants and aims to see if the drug helps patients complete their planned chemotherapy and reduces time spent in the hospital. The goal is to make treatment easier to tolerate, not to cure the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
-
University of Pennsylvania/Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.